ARCHIVES

Phase II Study Meets Primary Endpoint, Demonstrating Overall Survival of 5.2 Months

This article is from The Cancer Letter archive.

Vol. 36 No. 9 | September 27, 2013

Download PDF Visit The Full Archive

Related Articles

AACR Campaigns For Doubling Funding for Cancer Research In Three Years

April 25, 1997

NCI Names Brawly Director of Office of Special Populations

June 21, 1996

New Funding Mechanisms – Cooperative Agreement, Consortium Grant – Proposed For Clinical Groups

April 6, 1979

Phase IIb Trial of Vintafolide-Docetaxel Combination Meets Primary Endpoint of Progression-Free Survival

March 28, 2014

Michael Atkins Named Deputy Director at Georgetown Lombardi Cancer Center

March 2, 2012

Interview with Claudia Henschke: Observational Study Of Spiral CT Should Change Medical Practice, She Says.

November 3, 2006